Open access
Open access
Powered by Google Translator Translator

Randomized Trial: Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

9 Nov, 2018 | 02:55h | UTC

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome – New England Journal of Medicine (free)

Commentaries: Among heart attack survivors, drug reduces chances of second heart attack or stroke – University of Colorado Anschutz Medical Campus (free) AND Alirocumab Linked to Lower Risk for Recurrent Ischemic CV Events – NEJM Journal Watch (free)

“An estimated 49 patients would need to be treated for 4 years to prevent one CV event.” (from NEJM Journal Watch)

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.